JPMorgan Chase & Co. Cuts Charles River Laboratories International (NYSE:CRL) Price Target to $175.00

Charles River Laboratories International (NYSE:CRL) had its price target lowered by JPMorgan Chase & Co. from $215.00 to $175.00 in a report released on Monday,Benzinga reports. The brokerage currently has a neutral rating on the medical research company’s stock.

A number of other analysts have also recently issued reports on CRL. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research report on Monday, November 18th. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They issued a “sell” rating and a $151.00 price target on the stock. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Finally, The Goldman Sachs Group cut their target price on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Three investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $200.79.

Charles River Laboratories International Price Performance

NYSE:CRL opened at $165.70 on Monday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The stock has a market cap of $8.47 billion, a P/E ratio of 20.74, a PEG ratio of 6.25 and a beta of 1.37. The company has a fifty day moving average price of $181.99 and a 200 day moving average price of $194.26. Charles River Laboratories International has a one year low of $159.65 and a one year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. During the same quarter last year, the company earned $2.72 earnings per share. The firm’s revenue was down 1.6% on a year-over-year basis. Analysts anticipate that Charles River Laboratories International will post 10.17 earnings per share for the current year.

Institutional Investors Weigh In On Charles River Laboratories International

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRL. Cetera Investment Advisers increased its holdings in shares of Charles River Laboratories International by 2.4% in the second quarter. Cetera Investment Advisers now owns 9,969 shares of the medical research company’s stock valued at $2,059,000 after purchasing an additional 229 shares in the last quarter. Czech National Bank raised its position in shares of Charles River Laboratories International by 7.1% during the third quarter. Czech National Bank now owns 10,517 shares of the medical research company’s stock worth $2,072,000 after acquiring an additional 701 shares during the last quarter. Handelsbanken Fonder AB lifted its stake in shares of Charles River Laboratories International by 18.4% during the third quarter. Handelsbanken Fonder AB now owns 12,237 shares of the medical research company’s stock valued at $2,410,000 after acquiring an additional 1,900 shares during the period. GAMMA Investing LLC boosted its holdings in Charles River Laboratories International by 22.6% in the third quarter. GAMMA Investing LLC now owns 1,041 shares of the medical research company’s stock valued at $205,000 after acquiring an additional 192 shares during the last quarter. Finally, Fulton Bank N.A. raised its holdings in Charles River Laboratories International by 2.8% during the 3rd quarter. Fulton Bank N.A. now owns 3,396 shares of the medical research company’s stock worth $669,000 after purchasing an additional 91 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).